Eng Keong Tan, MD
Endocrinology, Diabetes & Metabolism · Carson City, NVNPI 1811339013
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.
Across 403 payments — averaging $30.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Medtronic$1K
- Lilly USA, LLC$1K
- Mannkind Corporation$788
- Boehringer Ingelheim$745
- Insulet Corporation$729
- plus $6K from 38 others
Across 1 payment — averaging $156.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$156
What the payments were for
- Travel & lodging$4954%
- Food & beverage$11,48795%
- Education$1651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,147 in reported general payments places this provider in the 75th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 32 | $544,857 |
| OzempicSemaglutide | 223 | $382,312 |
| TrulicityDulaglutide | 121 | $231,314 |
| JardianceEmpagliflozin | 144 | $218,778 |
| MounjaroTirzepatide | 118 | $196,443 |
| IsturisaOsilodrostat Phosphate | 11 | $154,433 |
| TymlosAbaloparatide | 25 | $75,954 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $69,071 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $59,625 |
| Tresiba Flextouch U-100Insulin Degludec | 63 | $55,719 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $55,050 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $47,017 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $37,524 |
| RybelsusSemaglutide | 13 | $35,197 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $31,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Crysvita | $151 | $544,85732 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,079 | $436,626257 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $631 | $435,400276 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $745 | $291,933190 claims |
| Recordati_rare_diseases_inc.Isturisa | $247 | $154,43311 claims |
| Radius Health, Inc.Tymlos | $409 | $75,95425 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $412 | $47,01729 claims |
| AstraZenecaFarxiga | $390 | $21,91818 claims |
| AbbVieSynthroid | $102 | $17,667171 claims |
| IBSA Pharma Inc.Tirosint | $52 | $4,59212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Carson City
- Joi HesterCarson City$9K
- John SuttonCarson City$8K
- Yee Liong LeeCarson City$5K
- Nitesh KuhadiyaReno$595K
- Samer NakhleLas Vegas$466K
- Quang NguyenHenderson$378K
- William LitchfieldHenderson$288K
- Chakravarthy KannanLas Vegas$144K
- Lisa AbbottReno$130K
- Michael Raymund GonzalesReno$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.